Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.61 |
| ▸ | BCR | P11274 | 13/20 | 0.61 |
| ▸ | KIT | P10721 | 8/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.61 |
| ▸ | LCK | P06239 | 3/20 | 0.61 |
| ▸ | CSF1R | P07333 | 3/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.61 |
| ▸ | SRC | P12931 | 3/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.61 |
| ▸ | FYN | P06241 | 2/20 | 0.61 |
| ▸ | LYN | P07948 | 2/20 | 0.61 |
| ▸ | FGR | P09769 | 2/20 | 0.61 |
| ▸ | BRAF | P15056 | 2/20 | 0.61 |
| ▸ | NQO2 | P16083 | 2/20 | 0.61 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.61 |
| ▸ | ABL2 | P42684 | 2/20 | 0.61 |
| ▸ | FRK | P42685 | 2/20 | 0.61 |
| ▸ | BLK | P51451 | 2/20 | 0.61 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5990469 | 0.90 | HIF1A (0.57) | ABL1BCRKITPDGFRAEGFR | |
| SCHEMBL2930443 | 0.86 | ABL1 (0.56) | ABL1BCRKITPDGFRACSF1R | |
| SCHEMBL8191704 | 0.83 | ABL1 (0.72) | ABL1BCRKITPDGFRAEGFR | |
| SCHEMBL23258781 | 0.83 | ABL1 (0.71) | ABL1BCRKITPDGFRAEGFR | |
| SCHEMBL715917 | 0.82 | LCK (0.56) | ABL1BCRKITPDGFRAEGFR | |
| SCHEMBL10075315 | 0.82 | ABL1 (0.70) | ABL1BCRKITPDGFRAEGFR | |
| SCHEMBL2317952 | 0.82 | ABL1 (0.70) | ABL1BCRKITPDGFRAEGFR | |
| SCHEMBL10109122 | 0.81 | ABL1 (0.72) | ABL1BCRKITPDGFRAEGFR | |
| SCHEMBL29198404 | 0.81 | ABL1 (0.74) | ABL1BCRKITPDGFRAEGFR | |
| SCHEMBL5004999 | 0.80 | ABL1 (0.60) | ABL1BCRKITPDGFRAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720853-B2 | PHARMACEUTICAL COMPOSITIONS OF THE 2 CRYSTALLINE FORM OF IMATINIB MESYLATE FOR USE IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA | NATCO PHARMA LTD (IN) | 2023-06-28 | — | — | EP | disclosed |
| WO-2013035102-A1 | PROCESSES FOR THE PREPARATION OF IMATINIB BASE AND INTERMEDIATES THEREOF | NATCO PHARMA LIMITED (IN) | 2013-03-14 | — | — | WO | disclosed |
| US-20130060030-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE | NATCO PHARMA LIMITED (IN) | 2013-03-07 | — | — | US | disclosed |
| EP-2547671-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE | Natco Pharma Limited (IN) | 2013-01-23 | — | — | EP | disclosed |
| US-8048883-B2 | Chronic Myelogenous Leukemia; crystal form stable at room temperature or higher temperatures up to 120 degrees C. and accelerated stress conditions, freely soluble in water; suspending Imatinib base in isopropanol and adding methane sulfonic acid at room temperature then cooling after reactoion | NATCO PHARMA LIMITED (IN) | 2011-11-01 | — | — | US | disclosed |
| WO-2011114337-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE | NATCO PHARMA LIMITED (IN) | 2011-09-22 | — | — | WO | disclosed |
| WO-2009060463-A1 | AN ENVIRONMENTALLY FRIENDLY PROCESS FOR THE PREPARATION OF IMATINIB BASE | NATCO PHARMA LIMITED (IN) | 2009-05-14 | — | — | WO | disclosed |
| WO-2008136010-A1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE IMATINIB BASE | NATCO PHARMA LIMITED (IN) | 2008-11-13 | — | — | WO | disclosed |
| US-20080255138-A1 | Novel Polymorphic Form Of Imatinib Mesylate And A Process For Its Preparation | NATCO PHARMA LIMITED (IN) | 2008-10-16 | — | — | US | disclosed |
| EP-1742933-A2 | CRYSTALLINE METHANESULFONIC ACID ADDITION SALTS OF IMATINIB | INSTYTUT FARMACEUTYCZNY (PL) | 2007-01-17 | — | — | EP | disclosed |
| US-20060111363-A1 | Treatment of uveal melanoma | ALL-ERICSSON CHARLOTTA | 2006-05-25 | — | — | US | disclosed |
| WO-2005095379-A2 | CRYSTALLINE METHANESULFONIC ACID ADDITION SALTS OF IMATINIB | INSTYTUT FARMACEUTYCZNY (PL) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111363-A1 | Treatment of uveal melanoma | MITF, ALDH1A2, UACA | ABL1 2500/4885BCR 4868/4885KIT 1141/4885 |
| US-20080255138-A1 | Novel Polymorphic Form Of Imatinib Mesylate And A Process For Its Preparation | ABL1, ABL2, BCR | ABL1 1/4885BCR 3/4885KIT 24/4885 |
| US-20130060030-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE IMATINIB BASE | ABL1, ABL2, FGFR1 | ABL1 1/4885BCR 51/4885KIT 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.